Lipoprotein Oxidation and Lipoprotein-lnduced Cell Injury in Diabetes

There is ample evidence that oxidized lipoproteines exist in vivo, not only in atherosclerotic lesions, but also associated with some experimental models of diabetes. Whether the lipoprotein oxidation is an eplphenomenon of other atherogenic or diabetogenic agents or processes or whether it is causally related to lesion formation in atherosclerosis or other forms of tissue damage in people with diabetes is unresolved. Intense Interest in testing these ideas derives from in vitro observations of the ways in which oxidized lipoproteines interact with cells that are unlike the Interactions with native lipoproteins. Many of these altered Interactions suggest known features of atherosclerotic lesions, and recent data show that antioxidant treatment reduces the progression of vascular lesions. There are reasons to believe that hyperglycemia may worsen lipid and lipoprotein oxidation. If this observation is the case in vivo, and If it is ultimately proved that lipoprotein oxidation facilltates lesion development, these events may help explain the accelerated atherosclerosis suffered by diabetic patients. The multiple pathways for which there is evidence that hyperglycemia may contribute to oxldative events—for example, by enhancing free radical production in stimulated inflammatory cells or by forming glycation products that can propagate free radical events—suggest avenues for further research and may ultimately indicate points for intervention in the various manifestations of the disease.

[1]  J. Farber,et al.  Mechanisms of cell injury by activated oxygen species. , 1994, Environmental health perspectives.

[2]  A. Verlangieri,et al.  Effects of d-alpha-tocopherol supplementation on experimentally induced primate atherosclerosis. , 1992, Journal of the American College of Nutrition.

[3]  A. Nègre-Salvayre,et al.  Ultraviolet-treated lipoproteins as a model system for the study of the biological effects of lipid peroxides on cultured cells. III. The protective effect of antioxidants (probucol, catechin, vitamin E) against the cytotoxicity of oxidized LDL occurs in two different ways. , 1991, Biochimica et biophysica acta.

[4]  A. Mooradian,et al.  Increased Serum Conjugated Dienes in Elderly Diabetic Patients , 1991, Journal of the American Geriatrics Society.

[5]  M. Freeman,et al.  Expression of type I and type II bovine scavenger receptors in Chinese hamster ovary cells: lipid droplet accumulation and nonreciprocal cross competition by acetylated and oxidized low density lipoprotein. , 1991, Proceedings of the National Academy of Sciences of the United States of America.

[6]  S. Kimura,et al.  Oxidative modification of glycated low density lipoprotein in the presence of iron. , 1991, Biochemical and biophysical research communications.

[7]  M. Penn,et al.  Relation between lipopolysaccharide-induced endothelial cell injury and entry of macromolecules into the rat aorta in vivo. , 1991, Circulation research.

[8]  M. Kuzuya,et al.  Probucol prevents oxidative injury to endothelial cells. , 1991, Journal of lipid research.

[9]  葛谷 雅文 Lipid peroxide and transition metals are required for the toxicity of oxidized low density lipoprotein to cultured endothelial cells , 1991 .

[10]  Urinary albumin, transferrin and iron excretion in diabetic patients. , 1991, Kidney international.

[11]  P. Henriksson,et al.  The antioxidant butylated hydroxytoluene protects against atherosclerosis. , 1991, Arteriosclerosis and thrombosis : a journal of vascular biology.

[12]  D. Steinberg,et al.  Role of oxidised low density lipoprotein in atherogenesis. , 1993, British heart journal.

[13]  S. Jain,et al.  Elevated lipid peroxidation levels in red blood cells of streptozotocin-treated diabetic rats. , 1991, Metabolism: clinical and experimental.

[14]  T. Nikkari,et al.  Oxidized low‐density lipoprotein is chemotactic for arterial smooth muscle cells in culture , 1990, FEBS letters.

[15]  N. Parinandi,et al.  Diabetic heart and kidney exhibit increased resistance to lipid peroxidation. , 1990, Biochimica et biophysica acta.

[16]  U. Steinbrecher Oxidatively modified lipoproteins , 1990 .

[17]  D. Morel,et al.  Activated human monocytes oxidize low-density lipoprotein by a lipoxygenase-dependent pathway. , 1990, Journal of immunology.

[18]  R. Cohen,et al.  Oxidized low density lipoproteins cause contraction and inhibit endothelium-dependent relaxation in the pig coronary artery. , 1990, The Journal of clinical investigation.

[19]  L. Yeh,et al.  The increase in lipid peroxidation in diabetic rat lens can be reversed by oral sorbinil. , 1990, Metabolism: clinical and experimental.

[20]  S. Ylä-Herttuala,et al.  Distribution of oxidation specific lipid-protein adducts and apolipoprotein B in atherosclerotic lesions of varying severity from WHHL rabbits. , 1990, Arteriosclerosis.

[21]  K. Bruckdorfer,et al.  Native and oxidized low‐density lipoproteins have different inhibitory effects on endothelium‐derived relaxing factor in the rabbit aorta , 1990, British journal of pharmacology.

[22]  K. Hirata,et al.  Lysophosphatidylcholine: essential role in the inhibition of endothelium-dependent vasorelaxation by oxidized low density lipoprotein. , 1990, Biochemical and biophysical research communications.

[23]  G. Chisolm,et al.  Oxidized low density lipoprotein suppresses the expression of tumor necrosis factor-alpha mRNA in stimulated murine peritoneal macrophages. , 1990, Journal of immunology.

[24]  D. Morel,et al.  Antioxidant treatment of diabetic rats inhibits lipoprotein oxidation and cytotoxicity. , 1989, Journal of lipid research.

[25]  S. Jain,et al.  Erythrocyte Membrane Lipid Peroxidation and Glycosylated Hemoglobin in Diabetes , 1989, Diabetes.

[26]  T. Carew,et al.  Initiation of atherosclerotic lesions in cholesterol-fed rabbits. I. Focal increases in arterial LDL concentration precede development of fatty streak lesions. , 1989, Arteriosclerosis.

[27]  A. Gown,et al.  Direct evidence for a protein recognized by a monoclonal antibody against oxidatively modified LDL in atherosclerotic lesions from a Watanabe heritable hyperlipidemic rabbit. , 1989, The American journal of pathology.

[28]  A Daugherty,et al.  Probucol attenuates the development of aortic atherosclerosis in cholesterol‐fed rabbits , 1989, British journal of pharmacology.

[29]  P. Cutler Deferoxamine Therapy in High-Ferritin Diabetes , 1989, Diabetes.

[30]  S. Savastano,et al.  Lipid peroxidation and human cataractogenesis in diabetes and severe myopia. , 1989, Experimental eye research.

[31]  O. Quehenberger,et al.  Modification of low density lipoprotein with 4-hydroxynonenal induces uptake by macrophages. , 1989, Arteriosclerosis.

[32]  J L Witztum,et al.  Beyond cholesterol. Modifications of low-density lipoprotein that increase its atherogenicity. , 1989, The New England journal of medicine.

[33]  S. Narumiya,et al.  Multiple receptors for modified low density lipoproteins in mouse peritoneal macrophages: different uptake mechanisms for acetylated and oxidized low density lipoproteins. , 1989, Biochemical and biophysical research communications.

[34]  D. Steinberg,et al.  A macrophage receptor that recognizes oxidized low density lipoprotein but not acetylated low density lipoprotein. , 1989, The Journal of biological chemistry.

[35]  J L Witztum,et al.  Low density lipoprotein undergoes oxidative modification in vivo. , 1989, Proceedings of the National Academy of Sciences of the United States of America.

[36]  L. Somova,et al.  Streptozotocin-induced diabetes in rat. II. Lipid and lipid peroxide changes of lipoprotein fractions in diabetes complicated by hypertension and myocardial infarction. , 1988, Methods and findings in experimental and clinical pharmacology.

[37]  T. Takano,et al.  Monoclonal DLR1a/104G antibody recognizing peroxidized lipoproteins in atherosclerotic lesions. , 1988, Biochimica et biophysica acta.

[38]  B. Sobel,et al.  Isolation of low density lipoprotein from atherosclerotic vascular tissue of Watanabe heritable hyperlipidemic rabbits. , 1988, Arteriosclerosis.

[39]  S. Weinbaum,et al.  Enhanced macromolecular permeability of aortic endothelial cells in association with mitosis. , 1988, Atherosclerosis.

[40]  S. Arimori,et al.  Increased Superoxide Production by Mononuclear Cells of Patients With Hypertriglyceridemia and Diabetes , 1988, Diabetes.

[41]  D. Steinberg,et al.  Lysophosphatidylcholine: a chemotactic factor for human monocytes and its potential role in atherogenesis. , 1988, Proceedings of the National Academy of Sciences of the United States of America.

[42]  G. Cazzolato,et al.  Presence of a Modified Low Density Lipoprotein in Humans , 1988, Arteriosclerosis.

[43]  J. Lunec,et al.  Vitamin C metabolites and microangiopathy in diabetes mellitus. , 1987, Diabetes research.

[44]  G. Chisolm,et al.  Modification of human serum low density lipoprotein by oxidation--characterization and pathophysiological implications. , 1987, Chemistry and physics of lipids.

[45]  T. Carew,et al.  Antiatherogenic effect of probucol unrelated to its hypocholesterolemic effect: evidence that antioxidants in vivo can selectively inhibit low density lipoprotein degradation in macrophage-rich fatty streaks and slow the progression of atherosclerosis in the Watanabe heritable hyperlipidemic rabbit. , 1987, Proceedings of the National Academy of Sciences of the United States of America.

[46]  A. Ooshima,et al.  Probucol prevents the progression of atherosclerosis in Watanabe heritable hyperlipidemic rabbit, an animal model for familial hypercholesterolemia. , 1987, Proceedings of the National Academy of Sciences of the United States of America.

[47]  G. Chisolm,et al.  Lipoprotein-mediated inhibition of endothelial cell production of platelet-derived growth factor-like protein depends on free radical lipid peroxidation. , 1987, The Journal of biological chemistry.

[48]  D. Steinberg,et al.  Oxidatively modified low density lipoproteins: a potential role in recruitment and retention of monocyte/macrophages during atherogenesis. , 1987, Proceedings of the National Academy of Sciences of the United States of America.

[49]  D. Morel,et al.  Toxicity of oxidized low‐density lipoprotein to cultured fibroblasts is selective for S phase of the cell cycle , 1987, Journal of cellular physiology.

[50]  A. Chait,et al.  Iron and copper promote modification of low density lipoprotein by human arterial smooth muscle cells in culture. , 1984, The Journal of clinical investigation.

[51]  D. Morel,et al.  Endothelial and Smooth Muscle Cells Alter Low Density Lipoprotein In Vitro by Free Radical Oxidation , 1984, Arteriosclerosis.

[52]  J L Witztum,et al.  Modification of low density lipoprotein by endothelial cells involves lipid peroxidation and degradation of low density lipoprotein phospholipids. , 1984, Proceedings of the National Academy of Sciences of the United States of America.

[53]  D. Morel,et al.  Low density lipoprotein cytotoxicity induced by free radical peroxidation of lipid. , 1983, Journal of lipid research.

[54]  L. J. Lewis,et al.  Lipoprotein Oxidation and Lipoprotein‐lnduced Cytotoxicity , 1983, Arteriosclerosis.

[55]  D. Steinberg,et al.  Enhanced Macrophage Degradation of Biologically Modified Low Density Lipoprotein , 1983, Arteriosclerosis.

[56]  D. Steinberg,et al.  INTERACTIONS OF PLASMA LIPOPROTEINS WITH ENDOTHELIAL CELLS * , 1982, Annals of the New York Academy of Sciences.

[57]  K. Pritchard,et al.  Restoration of Prostacyclin/Thromboxane A2 Balance in the Diabetic Rat: Influence of Dietary Vitamin E , 1982, Diabetes.

[58]  B. Arbogast,et al.  In Vitro Injury of Porcine Aortic Endothelial Cells by Very-Low-Density Lipoproteins from Diabetic Rat Serum , 1982, Diabetes.

[59]  Y. Higuchi Lipid Peroxides and α-Tocopherol in Rat Streptozotocin-Induced Diabetes Mellitus , 1982 .

[60]  T. Henriksen,et al.  Injury to human cells in culture induced by low density lipoprotein: an effect independent of receptor binding and endocytotic uptake of low density lipoprotein. , 1982, Scandinavian journal of clinical and laboratory investigation.

[61]  D. Steinberg,et al.  Enhanced macrophage degradation of low density lipoprotein previously incubated with cultured endothelial cells: recognition by receptors for acetylated low density lipoproteins. , 1981, Proceedings of the National Academy of Sciences of the United States of America.

[62]  K. Yagi,et al.  Lipid peroxide levels of serum lipoprotein fractions of diabetic patients. , 1981, Biochemical medicine.

[63]  G. Chisolm,et al.  LDL-induced cytotoxicity and its inhibition by HDL in human vascular smooth muscle and endothelial cells in culture. , 1979, Atherosclerosis.

[64]  N. Hotta,et al.  Lipid peroxide level in plasma of diabetic patients. , 1979, Biochemical medicine.

[65]  R. Lees,et al.  The distribution of labeled low-density lipoproteins across the rabbit thoracic aorta in vivo. , 1977, Atherosclerosis.